Max Hodak, the former president of Neuralink, announced via social media that he has invested in the company\'s competitor, Synchron. In July 2021, Synchron announced that it had received approval from the U.S. Food and Drug Administration (FDA) to begin the necessary trials for the future implementation of brain chips in humans. The Food and Drug Administration (FDA) is the U.S. government agency responsible for regulating food, drugs, cosmetics, medical devices, biological products, and blood products. In December, the company announced that one of its human trial patients, a man with amyotrophic lateral sclerosis (ALS), had used the device implanted in his brain to tweet the message: \"Hello World! Short tweet. Monumental progress.\"

hello, world! Short tweet. Monumental progress.

— Thomas Oxley (@tomoxl) December 23, 2021
On the one hand, Neuralink is working on a device that it wants to implant in people\'s brains to monitor and potentially stimulate brain activity. On the other hand, Synchron is developing a neural interface device, which accesses the brain through blood vessels. “Accessing the brain through blood vessels is an elegant idea, and after 10 years of work, @synchroninc recently announced the results of their first human patients; a great achievement. I\'m excited to get involved as an investor as they move from the bank to the bedside,” Max Hodak wrote on his Twitter account.

Accessing the brain via blood vessels is an elegant idea, and after 10y of work @synchroninc recently announced results from their first human patients; a huge accomplishment.

I’m excited to get involved as an investor as they go from bench to bedside.https://t.co/Lwo0M3T46T

— Max Hodak (@maxhodak_) February 4, 2022